# An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

> **NCT05385744** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 336 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BCD-132
- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT05385744
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-05
- **Primary completion:** 2022-09-09
- **Final completion:** 2023-09-29
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385744, "An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05385744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*